Loading…
← CockpitCompetitor Analysis › TRVI Trevi Therapeutics, Inc.Open in the cockpit ↗

Trevi Therapeutics, Inc.TRVICompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops Haduvio, an oral therapy for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.

Momentum weak 38
Mkt cap
$1.93B
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$21.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.9%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$13.51
1D0.0%
1W-8.8%
1M+5.3%
3M-26.0%
6M-2.7%
YTD+7.9%
1Y+19.0%
ATR %6.3%
Beta1.31
52w lowhigh33.2% off high

What Trevi Therapeutics does

Develops Haduvio, an oral therapy for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.

Has no product to sell, so it is funded by money raised from investors, and spending on trials sets its cash needs. Everything rests on whether the drug, nalbuphine in an extended-release tablet, shows benefit in cough studies and wins approval.

Products and services

  • Haduvio (chronic cough)

Customers

  • Pulmonologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Chronic cough/respiratory therapeutics

What could go right

  • Large underserved chronic cough market
  • Potential first oral US approval

What could go wrong

  • Clinical trial failure risk
  • Competitive P2X3 antagonist entrants

Moat: none (IP / patents). Addresses an underserved chronic cough market with no approved US treatments, but is still clinical-stage.

Headquarters: New Haven, Connecticut, US · Founded: 2009 · Employees: 34

Named competitors

Trevi Therapeutics at a glance

Size Trevi Therapeutics (TRVI) is a United States Health Care company (Biotechnology) with a market value of $1.93B, the 1798th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.51 on 18 Nov 2026.

Performance Over six months the shares fell 2.7%, against +11.2% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 19 in its peer set.

Short interest Short interest is 11.8% of the free float (30 Oct 2026).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 112TRVI 95
Six months, rebased to 100: Trevi Therapeutics against the median of its 20 peers (local-currency closes).

Trevi Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$140,000-$132,000-$147,000-$123,000-$43,000
EBITDA-$70.0M-$49.2M-$51.4M-$33.8M-$29.9M
Net income-$60.8M-$42.8M-$47.9M-$29.1M-$29.2M
Free cash flow-$61.7M-$42.1M-$38.3M-$31.8M-$28.3M
Capital expenditure$251,000$12,000$35,000$137,000$159,000
Total debt$527,000$753,000$1.03M$1.34M$9.18M

Quarterly statements and history in the cockpit →

Trevi Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%MRVI688520BCRXREPLSEPNTRAXVERACOAGZBIORXRXALMRSTOKTRVI6-month return →1-month return →
Up and to the right = strong over both horizons. Trevi Therapeutics is the large dot.

Trevi Therapeutics competitors and peer comparison

Head to head with its named competitors (TRVI vs MRK vs BAYN.DE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Trevi Therapeutics TRVI$1.93B-3%n/an/an/an/a
Merck & MRK$340B+23%+5%18%5.7×8.3%
Bayer BAYN.DE$60.3B+48%0%13%2.0×n/a

How Trevi Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Trevi Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureTRVIPeer medianRank in peer set
1-month return+5.3%-6.2%6th highest of 20
6-month return-2.7%+11.2%10th highest of 19
Distance from 52-week high-33.2%-32.4%11th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a

Questions

Who are Trevi Therapeutics's main competitors?
Named competitors: Merck (gefapixant, ex-US) (MRK), Bayer (BAYN.DE). The cockpit's measured peer set (industry) also includes Maravai Lifesciences (MRVI), Sinocelltech (688520.SS), BioCryst Pharmaceuticals (BCRX), Replimune (REPL), Septerna (SEPN), Immunome (IMNM).
How has Trevi Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -2.7% against +11.2% for the median peer; over one year +19.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.